Cargando…

Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment

Autosomal dominant polycystic kidney disease (ADPKD) causes pathological cystic changes to the kidney and is characterized by numerous renal and systemic manifestations. ADPKD is the fourth most common renal disease requiring renal replacement therapy. In this report, we present a detailed review of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barnawi, Rashid A, Attar, Rahaf Z, Alfaer, Sultan S, Safdar, Osama Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798550/ https://www.ncbi.nlm.nih.gov/pubmed/29440922 http://dx.doi.org/10.2147/IJNRD.S136359

Ejemplares similares

Is the end nigh?
Publicado: (2008)

Is the end nigh? : internationalism, global chaos and the destruction of the earth /
por: Lyons, Graham, 1936-
Publicado: (1995)

End of the world is nigh, scientists insist
por: Radford, T
Publicado: (2001)

End of the CMSSM coannihilation strip is nigh
por: Citron, M., et al.
Publicado: (2012)

Tolvaptan in ADPKD Patients With Very Low Kidney Function
por: Torres, Vicente E., et al.
Publicado: (2021)

The end is nigh: Colliding-atom research will consume the Earth
Publicado: (2008)

The end of the world is nigh... or is it science's greatest leap forward?
Publicado: (2008)

Effect of Tolvaptan Treatment on Acid−Base Homeostasis in ADPKD Patients
por: Bargagli, Matteo, et al.
Publicado: (2021)

Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD
por: Higashihara, Eiji, et al.
Publicado: (2021)

Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
por: Mizuno, Hiroki, et al.
Publicado: (2022)

Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD
por: Zhou, Xiaolei, et al.
Publicado: (2022)

Effects of Tolvaptan on Oxidative Stress in ADPKD: A Molecular Biological Approach
por: Rigato, Matteo, et al.
Publicado: (2022)

A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD
por: Perrone, Ronald D., et al.
Publicado: (2020)

Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD
por: Mallett, Andrew J., et al.
Publicado: (2021)

Urinary Aquaporin 2 as a Potential Indicator Predicting Tolvaptan Response in Patients With ADPKD
por: Makabe, Shiho, et al.
Publicado: (2021)

Author’s Reply to Correspondence: “Effect of Tolvaptan Treatment on Acid−Base Homeostasis in ADPKD Patients”
por: Heida, Judith E., et al.
Publicado: (2021)

Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Raina, Rupesh, et al.
Publicado: (2022)

The Light at the End of the Tunnel
por: Mando, Rufaat, et al.
Publicado: (2019)

As LHC draws nigh, nobelists outline dreams - and nightmares
Publicado: (2008)

Towards an equitable internship programme at WHO: is reform nigh?
por: Barnett-Vanes, Ashton, et al.
Publicado: (2016)

The Effect of Dietary Intervention on Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Patients on Tolvaptan and Their Quality of Life
por: Tarabzuni, Ola
Publicado: (2022)

Interaction Between Determinants Governing Urine Volume in Patients With ADPKD on Tolvaptan and its Impact on Quality of Life
por: Todorova, Polina, et al.
Publicado: (2023)

Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan
por: Gkekas, Eleftherios, et al.
Publicado: (2022)

10-Year Evaluation of Adherence and Satisfaction with Information about Tolvaptan in ADPKD: A Single-Center Pilot Study
por: Schirutschke, Holger, et al.
Publicado: (2021)

Case report: tolvaptan-associated creatine kinase elevation in two patients with autosomal dominant polycystic kidney disease (ADPKD)
por: Agraz-Pamplona, I., et al.
Publicado: (2020)

Light at end of the tunnel
por: Hassard, J
Publicado: (1989)

Light at the end of the tunnel
por: Manohar, Balaji
Publicado: (2013)

Light at the End of the Tunnel
por: Gupta, Piyush
Publicado: (2021)

Characteristics of Patients with End-Stage Kidney Disease in ADPKD
por: Shukoor, Shehbaz S., et al.
Publicado: (2020)

A case of patient with renal lupus with an initial presentation of hemolytic uremic syndrome triggered by streptococcal infection
por: Attar, Rahaf Z., et al.
Publicado: (2018)

2021: The Light at the End of the Tunnel?
por: Birkhoelzer, Sarah M., et al.
Publicado: (2021)

Light at the end of the tunnel of Corti
por: Hanlon, Kilian, et al.
Publicado: (2023)

Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report
por: Pellegrino, Angela Maria, et al.
Publicado: (2019)

Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry
por: Aiello, Valeria, et al.
Publicado: (2021)

Heterogeneous Cardiovascular Profiles in CKD: ADPKD Versus non-ADPKD
por: Au, Eric H.K., et al.
Publicado: (2022)

Tolvaptan
por: Rangarajan, Bharath, et al.
Publicado: (2014)

The light at the end of the tunnel gets brighter
por: Anaïs Schaeffer
Publicado: (2014)

Coronavirus Vaccine: Light at the End of the Tunnel
por: Ella, Krishna M, et al.
Publicado: (2020)

Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model
por: Bennett, Hayley, et al.
Publicado: (2019)

Antenatally Diagnosed ADPKD
por: Aldridge, Melanie, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_e4hkm58fc9gdmeuspjlkntje4s